

Clinical Trial Protocol

Iranian Registry of Clinical Trials

24 Sep 2021

Assessment of cinnamon effects on advanced glycation end products, plasma vascular and systematic inflammation factors, antioxidant status, NF-kB and Sirtuin1 activity in mononuclear cells in type 2 diabetic patients

Protocol summary

Summary

The main objective of the project "Determination of cinnamon effects on advanced glycation end products, plasma vascular and systematic inflammation factors, antioxidant status, NF-kB and Sirtuin 1 activity in mononuclear cells in type 2 diabetic patients". This clinical trial is a randomized, double-blind and placebo-controlled. Patients with type II diabetes clinics and medical centers in Tehran referred to the relevant elected in accordance with the inclusion and exclusion criteria. The sample size was estimated for each group of 20 patients, including 10% loss, 22 patients in each group and a total of 44 patients, respectively. In this study, patients with type II diabetes who are eligible to study the subject, objectives and methodology is explained study, If you wish to participate in this study are patients informed consent is obtained. The patients were divided into 2 groups using random numbers table. In order to execute a double-blind study, at baseline set by anyone other than the researchers encoded packets containing the capsules to lack of knowledge of the capsules received by each group is maintained. The patients in the supplement group capsules of cinnamon, cinnamon supplement capsules at baseline package is for 8 weeks. The patients in the supplement group cinnamon capsules daily 3 grams of cinnamon supplementation (capsules 1 gr cinnamon, 3 times per day) during the study receive 8 weeks. Patients in the control group at baseline capsules packages placebo (microcrystalline cellulose) that are similar to cinnamon supplement capsules for 8 weeks is and the patient is asked to capsules 1 gr microcrystalline cellulose, 3 times per day, use .

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT2016061128392N1**

Registration date: **2016-07-01, 1395/04/11**

Registration timing: **registered_while_recruiting**

Last update:

Update count: **0**

Registration date

2016-07-01, 1395/04/11

Registrant information

Name

Behrouz Talaei

Name of organization / entity

Shahid Beheshti University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 912 558 1202

Email address

b_talaei@nnftri.ac.ir

Recruitment status

Recruitment complete

Funding source

National Nutrition & Food Technology Research Institute (NNFTRI) (Shahid Beheshti University of Medical Sciences Faculty of Nutrition Sciences and food technology) and Research Institute for Endocrine Sciences Shahid Beheshti University of Medical Sciences

Expected recruitment start date

2016-03-19, 1394/12/29

Expected recruitment end date

2017-03-19, 1395/12/29

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Assessment of cinnamon effects on advanced glycation end products, plasma vascular and systematic inflammation factors, antioxidant status, NF-kB and Sirtuin1 activity in mononuclear cells in type 2 diabetic patients

Public title

Assessment of cinnamon effects in type 2 diabetic patients

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria : Having type 2 diabetes for at least 10 years: FBS <180 and 2 h-blood-sugar <250 mg/dl: no pregnancy or lactation: no autoimmune disorder: without any thyroid , kidney , CVD diseases, thyroid and chronic inflammatory diseases, peptic ulcer and infection: no regular consumption of cinnamon or other herbal drugs: no sensitivity People who are just using the pills (not insulin): your diabetes control cinnamon: body mass index (BMI) <30 kg/m : Age between 70-25 years.

Exclusion criteria : No observation of research protocol (no consumption of more than 20% of the capsules): any sensitivity due to cinnamon consumption reported by the patient or noticed after the outset of the study: consumption of alcohol or narcotic drugs: and any variation in patients' routine treatment according to physicians' resolution (i.e., variation in type and dose of the drugs to be consumed, and treatment with insulin): Pregnancy during the study.

Age

From **70 years** old to **25 years** old

Gender

Both

Phase

1-2

Groups that have been masked

No information

Sample size

Target sample size: **44**

Randomization (investigator's opinion)

Randomized

Randomization description**Blinding (investigator's opinion)**

Double blinded

Blinding description**Placebo**

Used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

National Nutrition & Food Technology Research Institute (NNFTRI)

Street address

NO 7, St. shahid hafizi, West town, Tehran

City

Tehran

Postal code

1981619573

Approval date

2016-03-12, 1394/12/22

Ethics committee reference number

IR.SBMU.nnftri.Rec.1394.36

Health conditions studied**1****Description of health condition studied**

DIABETES

ICD-10 code

E11.9

ICD-10 code description

Non-insulin-dependent diabetes mellitus without complications

Primary outcomes**1****Description**

Sirtuin Activity 1

Timepoint

Before and after the intervention.

Method of measurement

ng/ml

2**Description**

Fasting insulin

Timepoint

Before and after the intervention

Method of measurement

mU/L

3**Description**

HOMA-IR

Timepoint

Before and after the intervention

Method of measurement

%

4

Description

Fasting plasma glucose

Timepoint

Before and after the intervention

Method of measurement

mg/dl

5

Description

Carboxymethyl-lysine plasma

Timepoint

Before and after the intervention

Method of measurement

ng/ml

6

Description

Hb A1c

Timepoint

Before and after the intervention

Method of measurement

%

7

Description

The activity NF-kB

Timepoint

Before and after the intervention

Method of measurement

ng/ml

8

Description

VCAM-1

Timepoint

Before and after the intervention

Method of measurement

ng/ml

9

Description

hs-CRP

Timepoint

Before and after the intervention

Method of measurement

ng/ml

10

Description

IL-6

Timepoint

Before and after the intervention

Method of measurement

ng/L

11

Description

TNF

Timepoint

Before and after the intervention

Method of measurement

ng/L

12

Description

ICAM-1

Timepoint

Before and after the intervention

Method of measurement

ng/ml

Secondary outcomes

1

Description

Vitamin E diet

Timepoint

Before and after the intervention

Method of measurement

mg/day

2

Description

MUFA

Timepoint

Before and after the intervention

Method of measurement

gr/day

3

Description

PUFA

Timepoint

Before and after the intervention

Method of measurement

gr/day

4

Description

Salt diet

Timepoint

Before and after the intervention

Method of measurement

gr/day

5

Description

SAFA

Timepoint

Before and after the intervention.

Method of measurement

gr/day

6

Description

Fat Diet

Timepoint

Before and after the intervention.

Method of measurement

gr/day

7

Description

Cholesterol diet

Timepoint

Before and after the intervention

Method of measurement

mg/day

8

Description

Dietary fiber

Timepoint

Before and after the intervention

Method of measurement

mg/day

9

Description

Protein Diet

Timepoint

Before and after the intervention

Method of measurement

gr/day

10

Description

BMI

Timepoint

Before and after the intervention

Method of measurement

Kilograms per square meter

11

Description

Carb Diet

Timepoint

Before and after the intervention

Method of measurement

gr/day

12

Description

Total dietary energy

Timepoint

Before and after the intervention

Method of measurement

Kcal/day

13

Description

Vitamin C diet

Timepoint

Before and after the intervention

Method of measurement

mg/day

14

Description

Selenium diet

Timepoint

Before and after the intervention

Method of measurement

mcg/day

Intervention groups

1

Description

The intervention group: capsules 1 gr Cinnamon, 3 times per day, for 8 weeks.

Category

Treatment - Drugs

2

Description

Control group: capsules 1 gr microcrystalline cellulose, 3 times per day, for 8 weeks.

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Tehran Erfan Hospital

Full name of responsible person

Behrouz Talaei

Street address

City

Tehran

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

National Nutrition & Food Technology Research Institute (NNFTRI)

Full name of responsible person

DR.Parvin Mirmiran

Street address

NO 7, St. shahid hafiz, West town, Tehran

City

Tehran

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

National Nutrition & Food Technology Research Institute (NNFTRI)

Proportion provided by this source

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

empty

2

Sponsor

Name of organization / entity

Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences

Full name of responsible person

dr.Parvin Mirmiran

Street address

Next to Taleghani Hospital, Velenjak

City

Tehran

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences

Proportion provided by this source

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

empty

Person responsible for general inquiries

Contact

Name of organization / entity

Shahid Beheshti University of Medical Sciences
Faculty of Nutrition Sciences and food technology

Full name of responsible person

Behrouz Talaei

Position

PhD Student, Nutrition Sciences

Other areas of specialty/work

Street address

NO 7, St. shahid hafizi, West town, Tehran

City

Tehran

Postal code

Phone

+98 21 2236 0656

Fax

Email

B_TALAEI@HOTMAIL.COM

Web page address

Person responsible for scientific inquiries

Contact

Name of organization / entity

Shahid Beheshti University of Medical Sciences

Full name of responsible person

dr.Parvin Mirmiran

Position

PhD Nutrition

Other areas of specialty/work

Street address

NO 7, St. shahid hafizi, West Town, Tehran

City

Tehran

Postal code

Phone

+98 21 2236 0656

Fax

Email

B_TALAEI@HOTMAIL.COM ,
parvin.mirmiran@gmail.com

Web page address

Person responsible for updating data

Contact

Name of organization / entity

Shahid Beheshti University of Medical Sciences

Full name of responsible person

Behrouz Talaei

Position

PhD Student, Nutrition Sciences

Other areas of specialty/work

Street address

City

Tehran

Postal code

Phone

+98 21 2236 0656

Fax

Email

B_TALAEI@HOTMAIL.COM

Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)

empty

Study Protocol

empty
Statistical Analysis Plan
empty
Informed Consent Form
empty
Clinical Study Report

empty
Analytic Code
empty
Data Dictionary
empty